Sphingolipid metabolism potential in fecal microbiome and bronchiolitis in infants: a case–control study

Hasegawa, Kohei; Stewart, Christopher J.; Mansbach, Jonathan M.; Linnemann, Rachel W.; Ajami, Nadim J.; Petrosino, Joseph F.; Camargo, Carlos A.

doi:10.1186/s13104-017-2659-9

BMC Research Notes

Table 4 Predicted KEGG pathways with significant differences in relative abundance between infants with bronchiolitis and healthy controls

From: Sphingolipid metabolism potential in fecal microbiome and bronchiolitis in infants: a case–control study

KEGG pathway	Difference in relative abundance				Correlation with Bacteroides abundance
KEGG pathway	Mean abundance in cases (%)	Mean abundance in controls (%)	Raw P value	FDR corrected q value	Spearman’s rho	P value
ko00051; fructose and mannose metabolism	1.691	1.447	0.001	0.043	0.55	<0.001
ko00052; galactose metabolism	1.473	1.298	0.004	0.035	0.66	<0.001
ko00140; steroid hormone biosynthesis	0.098	0.063	0.007	0.049	0.66	<0.001
ko00190; oxidative phosphorylation	1.332	1.215	0.005	0.041	0.41	<0.001
ko00311; penicillin and cephalosporin biosynthesis	0.068	0.060	0.001	0.041	0.44	<0.001
ko00450; selenocompound metabolism	0.626	0.703	0.001	0.046	−0.61	<0.001
ko00460; cyanoamino acid metabolism	0.280	0.222	0.004	0.037	0.82	<0.001
ko00472; d-arginine and d-ornithine metabolism	0.001	0.002	0.004	0.037	−0.52	<0.001
ko00480; glutathione metabolism	0.678	0.764	0.001	0.035	−0.49	<0.001
ko00511; other glycan degradation	1.198	0.910	0.002	0.035	0.72	<0.001
ko00520; amino sugar and nucleotide sugar metabolism	2.751	2.450	0.002	0.037	0.77	<0.001
ko00523; polyketide sugar unit biosynthesis	0.196	0.163	0.002	0.035	0.80	<0.001
ko00531; glycosaminoglycan degradation	0.256	0.152	0.005	0.044	0.73	<0.001
ko00532; glycosaminoglycan biosynthesis	0.035	0.026	0.001	0.048	0.72	<0.001
ko00591; linoleic acid metabolism	0.120	0.113	0.006	0.047	0.52	<0.001
ko00600; sphingolipid metabolism	0.489	0.351	0.003	0.034	0.77	<0.001
ko00603; glycosphingolipid biosynthesis	0.134	0.097	0.003	0.031	0.73	<0.001
ko00604; glycosphingolipid biosynthesis	0.061	0.039	0.006	0.048	0.74	<0.001
ko00642; Ethylbenzene degradation	0.084	0.075	0.002	0.034	0.25	0.001
ko00660; C5-branched dibasic acid metabolism	0.171	0.191	<0.001	0.028	−0.50	<0.001
ko00940; phenylpropanoid biosynthesis	0.213	0.163	0.006	0.048	0.81	<0.001
ko00944; flavone and flavonol biosynthesis	0.015	0.009	0.002	0.036	0.77	<0.001
ko03015; mRNA surveillance pathway	0.003	0.001	0.003	0.032	0.80	<0.001
ko04141; protein processing in endoplasmic reticulum	0.063	0.049	0.006	0.049	0.69	<0.001
ko04142; lysosome	0.310	0.194	0.006	0.047	0.76	<0.001
ko04210; apoptosis	0.043	0.025	0.002	0.030	0.69	<0.001
ko04612; antigen processing and presentation	0.014	0.010	0.002	0.031	0.58	<0.001
ko04621; NOD-like receptor signaling pathway	0.056	0.042	0.001	0.040	0.74	<0.001
ko04721; synaptic vesicle cycle	0.001	0.000	0.002	0.033	0.58	<0.001
ko04725; cholinergic synapse	0.002	0.005	0.003	0.031	−0.12	0.14
ko04914; progesterone-mediated oocyte maturation	0.014	0.010	0.002	0.033	0.58	<0.001
ko04930; type II diabetes mellitus	0.026	0.028	0.001	0.036	−0.47	<0.001
ko04962; vasopressin-regulated water reabsorption	0.001	0.000	0.002	0.036	0.58	<0.001
ko05110; vibrio cholerae infection	0.001	0.004	0.006	0.046	−0.41	<0.001
ko05133; pertussis	0.356	0.609	0.002	0.029	−0.24	0.03
ko05211; renal cell carcinoma	0.013	0.019	<0.001	0.028	−0.58	<0.001
ko05215; prostate cancer	0.016	0.011	0.002	0.037	0.63	<0.001

Italics results are the pathways of interest (sphingolipid metabolic pathways)

Back to article page

ISSN: 1756-0500

Contact us

Submission enquiries: bmcresearchnotes@biomedcentral.com
General enquiries: ORSupport@springernature.com